A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatric formulations using a 100 mg tablet formulation as the reference, with and without food.
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Bedaquiline (Primary)
- Indications Tuberculosis
- Focus Pharmacokinetics
- 19 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 May 2013 Planned end date changed from 26 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.